Signals Blog
Menu

Explaining the hype: CAR T-cells

With the start of a new year, I like to take a moment to think about what things in cancer research got me really excited the previous year. Beyond a doubt, that thing for me in 2017 was the first (and second!) FDA approval of a CAR T-cell (chimeric antigen receptor...

Right Turn: Unwrapping bubble boy disease

Before Jake Gyllenhaal starred in the 2001 comedy Bubble Boy, there was a 1976 version starring John Travolta called The Boy In The Plastic Bubble. Both movies were inspired by the lives of David Vetter, who had severe combined immunodeficiency (SCID), and Ted DeVita,...

Right Turn: Genes are this season’s hottest trend

In what feels like back-to-back news, the U.S. Food and Drug Administration (FDA) has approved two gene therapies for cancer. The actual announcements happened seven weeks apart, but for patients, manufacturers, investors and shareholders, it’s like Christmas – over...

Right Turn: A user’s guide to debunking health goop

Do you recognize the name Timothy Caulfield? How about if I tell you that he took on Gwyneth Paltrow and her Goop empire in his popular 2015 book Is Gwyneth Paltrow Wrong About Everything? Caulfield is a professor of health law and science policy at the University of...

‘Bad Luck 2.0’ – the transformation to success

Over two years ago, an article published in Science took the Internet and media by storm. The paper, “Variation in cancer risk among tissues can be explained by the number of stem cell divisions,” better known as “The ‘Bad Luck’ Cancer Study,” used mathematical...

Right Turn: ‘Right to try’ state of affairs in U.S.

On Tuesday, August 29, Signals is hosting a blog carnival on the topic Right to Try. Before you read the perspectives of the contributing bloggers, here’s what President Trump thinks about the legislation and the Goldwater Institute’s reaction. It’s the Institute that...